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Abstract
Background: Serum methylmalonic acid (MMA) is regarded as a sensitive marker of vitamin B-12 status. Elevated
circulating MMA is linked to neurological abnormalities. Contribution of age, supplement use, kidney dysfunction,
and vitamin B-12 deficiency to high serum MMA in post-folic acid fortification period is unknown.
Methods: We investigated prevalence, population attributable risk (PAR), and PAR% for high MMA concentrations
in the US. Data from 3 cross-sectional National Health and Nutrition Examination Surveys conducted in post-folic
acid fortification period were used (n = 18569).
Results: Likelihood of having high serum MMA for white relative to black was 2.5 (P < 0.0001), ≥ 60 y old persons
relative to < 60 y old persons was 4.0 (P < 0.0001), non-supplement users relative to supplement users was 1.8 (P
< 0.0001), persons with serum creatinine ≥ 130 μmol/L relative to those with < 130 μmol/L was 12.6 (P < 0.0001),
and persons with serum vitamin B-12 < 148 pmol/L relative to those with ≥ 148 pmol/L was 13.5 (P < 0.0001). PAR
% for high MMA for old age, vitamin B-12 deficiency, kidney dysfunction, and non-supplement use were 40.5, 16.2,
13.3, and 11.8, respectively. By improving serum vitamin B-12 (≥ 148 pmol/L), prevalence of high MMA would be
reduced by 16-18% regardless of kidney dysfunction.
Conclusions: Old age is the strongest determinant of PAR for high MMA. About 5 cases of high serum MMA/1000
people would be reduced if vitamin B-12 deficiency (< 148 pmol/L) is eliminated. Large portion of high MMA
cases are not attributable to serum vitamin B-12. Thus, caution should be used in attributing high serum MMA to
vitamin B-12 deficiency.
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Introduction
Elevated circulating methylmalonic acid (MMA) is an
emerging potential risk factor for neurodegenerative dis-
eases and thus may be neurotoxic [1,2]. MMA interferes
with energy production in mitochondria by inhibiting
electron transport complex II [3,4]. Epidemiological stu-
dies have linked high circulating MMA with declined
cognitive function [5,6]. Doubling serum MMA concen-
tration from 0.25 to 0.50 μmol//L was associated with >
50% more rapid cognitive decline in a longitudinal study
conducted in the UK [5]. In another longitudinal study
in the US, serum MMA concentrations were predictive
of rapid cognitive decline in older subjects [6].
Serum MMA is considered as a sensitive marker of
tissue vitamin B-12 deficiency [7,8]. Although serum
vitamin B-12 is widely used as a marker of vitamin B-12
deficiency [9], serum vitamin B-12 may not always
reflect true vitamin B-12 status because some indivi-
duals with low-normal vitamin B-12 exhibit tissue vita-
min B-12 deficiency [10]. In vitamin B-12 deficiency,
serum MMA is derived from L-methylmalonyl CoA due
to impaired function of methylmalonyl CoA mutase
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[11]. Adenosylcobalamin, a coenzyme of vitamin B-12, is
required for the function of methylmalonyl CoA mutase,
which converts methylmalonyl CoA to succinyl CoA
[12].
Beginning January 1 1998, the FDA mandated that all
processed cereals be fortified with folic acid in order to
reduce the risk of neural tube defects (NTD) in new-
born [13,14]. As a result, NTDs are reduced by 19%
[15,16] owing to improved folate status [17-20]. Second-
ary to reduction in NTD, folic acid fortification has low-
ered circulating total homocysteine (tHcy) [17,18,21]
and prevalence of anemia [22]. There are some concerns
regarding possible negative impact of high folate status
following folic acid fortification in those with vitamin B-
12 deficiency [23-25]. These concerns stem from reports
suggesting that high folic acid intake may lead to the
correction of hematological abnormalities associated
with vitamin B-12 deficiency [26,27] which may lead to
delay in diagnosis of vitamin B-12 deficiency leading to
irreversible neuropathy [28,29]. Although the precise
mechanism through which high folate status causes
harm in those with vitamin B-12 deficiency is not
known, recently, Selhub et al [30] very elegantly pro-
posed how high serum MMA associated with low vita-
min B-12 and high folate status disrupts vitamin B-12
homeostasis.
Vitamin B-12 status and kidney function are two
important determinants of MMA [31-33]. Prevalence of
high serum MMA in older Americans was 20% in the
pre-folic acid fortification period [31]. In this study, we
used nationally representative surveys to yield large sam-
ple size. Because serum MMA is regarded as a sensitive
marker of vitamin B-12 deficiency and is elevated in kid-
ney dysfunction, a common condition in older persons
and that elevated MMA is related to negative health
outcomes [1-6], it is important to know the contribution
of vitamin B-12 deficiency, kidney dysfunction, and
older age to the burden of circulating high MMA.
Moreover, there are very limited data on serum MMA
and its relation with race-ethnicity [34]. Therefore, the
objective of this study was to investigate population pre-
valence estimates, population attributable risk (PAR),
and PAR% for high serum MMA in the post-folic acid
fortification period for US population.
Methods and Subjects
Description of survey and study sample
National Health and Nutrition and Examination Surveys
(NHANES) are based on a complex, stratified, multi-
stage probability sample survey conducted by National
Center for Health Statistics (NCHS). Demographic,
socioeconomic, dietary, and health related data were col-
lected in the participants’ home as part of the household
interview. A physician administered examination
component is part of the assessment done on household
interviewed persons in Mobile Examination Centers
(MEC). Rest of the examination assessment on indivi-
duals is performed by health technicians in MEC. In
NHANES, young children, older persons, non-Hispanic
black, and Mexican American/Hispanic were over-
sampled to yield reliable estimates for these groups.
Beginning 1999, NHANESs were conducted as contin-
uous, annual surveys rather than the periodic surveys. In
this study, NHANES 1999-2000 [35], NHANES 2001-
2002 [36], and NHANES 2003-2004 [37] were concate-
nated into one analytic database, NHANES 1999-2004,
as per guidelines from the NCHS. The description of
these surveys has been reported in detail elsewhere
[38-40]. Briefly, NHANES 1999-2000 was conducted
between March 1999 and December 2000 on 9965 indi-
viduals (all were home interviewed; 9282 were examined
in MECs); NHANES 2001-2002 was conducted between
January 2001 and December 2002 on 11039 individuals
(all were home interviewed; 10477 were examined in
MECs); and NHANES 2003-2004 was conducted
between January 2003 and December 2004 on 12761
individuals (10122 were home interviewed; 9643 were
examined in MECs).
The combined 3 cycles of NHANES 1999-2004
yielded a sample size of 31126. In data analysis, indivi-
duals who reported their race-ethnicity as “Other” were
excluded (n = 884). This “Other” category represented
people with mixed races and individuals belonging to
race-ethnicities other than non-Hispanic white, non-His-
panic black, or Mexican American/Hispanic. There were
no missing data for sex, age, and race-ethnicity. Indivi-
duals with missing data for supplement use (n = 28),
serum creatinine (n = 4093), serum vitamin B-12 (n =
18), and serum MMA (n = 7534) were excluded. After
applying the aforementioned exclusion criteria, the final
study sample consisted of 18569 subjects. Sample size
for persons with normal kidney function was 18238.
Measurements
Depending on the age of the participant, data were col-
lected on body measurements, demography, physical
function, health condition, lifestyle behaviors, biochem-
ical measurements of blood and urine, and diet intake.
Because we used serum creatinine as one of the vari-
ables related to serum MMA and in NHANES serum
creatinine concentrations were measured only in per-
sons > 12 y old age, this current study was based on the
sample > 12 y old age group. Other variables such as
supplement use, serum vitamin B-12, and serum MMA
had no impact on the age of this study sample. Blood
was collected from venipuncture in the MECs according
to the standard protocols. Individuals who took vitamin/
mineral supplements 1 month prior to the survey were
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categorized as supplement users. Serum MMA was mea-
sured using gas chromatography/mass spectrophotome-
try. Serum vitamin B-12 was measured using
Quantaphase II radioassay kit (Biorad Laboratories, Her-
cules, CA). Serum creatinine was measured using an
autoanalyzer (Hitachi Model 917 for NHANES 1999-
2002; Beckman Synchron LX20 for NHANES 2003-
2004). Sex, race-ethnicity, age, supplement use, serum
creatinine, and serum vitamin B-12 were selected as
important variables that are associated with serum
MMA concentrations. Detailed methodology on labora-
tory procedures are described elsewhere [41-43].
Serum concentration of > 350 nmol/L was used to
define high MMA [44]. Serum creatinine concentrations
≥ 130 μmol/L was used to indicate impaired kidney
function [45]. Vitamin B-12 deficiency was defined as
having serum vitamin B-12 concentrations < 148 pmol/
L [30,31,46].
Statistical analysis
SUDAAN (SAS-callable) statistical software (SUDAAN
for Windows, version 10.0, Research Triangle Institute,
Research Triangle Park, NC) was used to account for
complex survey design. In data analysis, to account for
differential probabilities of selection and adjustments for
non-coverage and non-response bias, sample weights,
primary sampling units, and stratification variables were
included as per NCHS’s guidelines. Also, SAS (SAS for
Windows, version 9.1, SAS Institute Inc, Cary, NC) was
used in conjunction with SUDAAN to manage and ana-
lyze data files.
Because of non-normality distribution of serum MMA
concentrations, natural logarithmic transformation was
used to satisfy the requirement for normality. Standard
errors were generated with Taylor Linearization Series
as this method takes the complex NHANES design and
sampling in to account. Odds ratio (OR) and 95% confi-
dence intervals (CI) were determined for serum MMA >
350 nmol/L with multivariate logistic regression analysis.
Statistical significance was set at P < 0.05.
PAR (prevalence of a condition/disease in the popula-
tion due to the presence of risk factor or prevalence of a
condition/disease in the population that would be
reduced if risk factor was removed) and PAR% (percent
of prevalence of a condition/disease in the population
due to presence of risk factor or percent of prevalence
of a condition/disease in the population that would be
reduced if risk factor was removed) for serum MMA >
350 nmol/L were calculated for non-Hispanic white
relative to combined non-Hispanic black and Mexican
American/Hispanic (non-white), older persons (≥ 60 y)
relative to younger persons (< 60 y), non-supplement
users relative to supplement users, persons with serum
creatinine ≥ 130 μmol/L relative to serum creatinine <
130 μmol/L, and persons with serum vitamin B-12 <
148 pmol/L relative to serum vitamin B-12 ≥ 148 pmol/
L. Non-Hispanic white, older persons (≥ 60 y), nonsup-
plement users, persons with serum creatinine ≥ 130
μmol/L, and persons with serum vitamin B-12 < 148
pmol/L were used as persons at risk for high serum
MMA concentrations. Their counterparts, non-non-His-
panic white (non-white), younger persons (< 60 y), sup-
plements users, persons with serum creatinine < 130
μmol/L, and persons with serum vitamin B-12 ≥ 148
pmol/L were used as referent groups. In order to create
a dichotomous variable for race-ethnicity, persons of
non-Hispanic black and Mexican American/Hispanic
were combined into one category, non-non-Hispanic
white (non-white). This enabled us to compare white
with non-white population. Age variable was divided
into < 60 y and ≥ 60 y old categories to create a dichot-
omized variable. We chose this age cut off because the
serum MMA concentrations started in increase more
around the age of 60 y based on our initial observation
of serum MMA in this study sample. PAR and PAR%
were not calculated for sex because this variable was not
significantly related to serum MMA in the logistic
regression (P = 0.98). All PAR and PAR% calculations
were based on weighted sample. Because in kidney dys-
function, MMA concentrations are elevated, PAR and
PAR% also calculated after excluding persons with
serum creatinine ≥ 130 μmol/L. This allowed us to
assess the impact of kidney dysfunction on PAR and
PAR% for serum MMA. Formulas for calculation of
PAR and PAR% for high serum MMA are given below
[47,48].
PAR = (Prevalence of high MMATotal sample × 100)− (Prevalence of high MMAReferent group ×100)
PAR% =
Prevalence of high MMATotal sample − Prevalence of high MMAReferent group
Prevalence of high MMATotal sample
×100
Prevalence of high MMATotal sample = Cases of high MMATotal sample
/
Sample sizeTotal




After excluding missing values, 18569 persons had mea-
sured serum MMA concentrations in NAHNES 1999-
2004. Men were ≈49% (n = 9020), women were ≈51% (n
= 9549), non-Hispanic white were ≈44% (n = 8170),
non-Hispanic black were ≈23% (n = 4351), Mexican
American/Hispanic were ≈33% (n = 6048), adolescents
(12 - < 18 y) were ≈24% (n = 4546), and older persons
(≥ 60 y) were ≈24% (n = 4427). About 41% of the study
participants reported that they consumed supplements
during 1 month prior to the survey (Table 1).
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Prevalence (%) and ORs (95% CI) for high serum
MMA by sex, race-ethnicity, age, supplement use, serum
creatinine, and serum vitamin B-12 for US population in
the post-folic acid fortification period are presented in
Table 2. Overall prevalence of high serum MMA was
3.1%. Odds of having high serum MMA was signifi-
cantly higher in non-Hispanic white (prevalence, 3.4%;
OR, 2.48; P < 0.001) and Mexican American/Hispanic
(prevalence, 3.0%; OR, 2.77; P < 0.0003) relative to non-
Hispanic black (prevalence, 0.2%), significantly higher in
persons ≥ 60 y old (prevalence, 8.3%; OR, 4.0; P <
0.0001) relative to persons < 60 y old (prevalence, 1.9%),
significantly higher in nonsupplement users (prevalence,
3.5%; OR, 1.82; P < 0.0001) relative to supplement users
(prevalence, 2.8%), significantly higher in persons with
serum creatinine ≥ 130 μmol/L (prevalence, 34.1%; OR,
12.6; P < 0.0001) relative to persons with serum creati-
nine < 130 μmol/L (prevalence, 2.7%), and significantly
higher in persons with serum vitamin B-12 < 148 pmol/
L (prevalence, 27.6%; OR, 13.5; P < 0.0001) relative to
persons with serum vitamin B-12 ≥ 148 pmol/L (preva-
lence, 2.6%). Sex was not significantly related to high
MMA concentrations (P = 0.98).
After excluding persons with high serum creatinine (≥
130 μmol/L), prevalence (%) and ORs (95% CI) for high
serum MMA by race-ethnicity, age, supplement use, and
serum vitamin B-12 for US population in the post-folic
acid fortification period are presented in Table 3. Over-
all, prevalence of high serum MMA in those with nor-
mal renal function was 2.7%. In this population, age,
race-ethnicity, supplement use, and serum vitamin B-12
were significantly related to serum high MMA. Likeli-
hood of having high serum MMA was significantly
lower in non-Hispanic black relative to non-Hispanic
white (0.8% vs. 2.8%; OR, 0.28; P < 0.0001), significantly
higher in ≥ 60 y old persons relative to < 60 y old per-
sons (6.8% vs. 1.8%; OR, 4.38; P < 0.0001), significantly
higher in nonsupplement users relative to supplement
users (3.1% vs. 2.3%; OR, 1.93; P < 0.0001), and signifi-
cantly higher in those with vitamin B-12 < 148 pmol/L
compared to those with vitamin B-12 ≥ 148 pmol/L
(26.3% vs. 2.2%; OR, 13.3, P < 0.0001).
PAR and PAR% for high serum MMA by race-ethni-
city, age, supplement use, serum creatinine, and serum
vitamin B-12 for US population in the post-folic acid
fortification period are presented in Table 4. PARs for
serum MMA > 350 nmol/L were ≈8 cases/1000 people
(0.774) for non-Hispanic white relative to non-non-His-
panic white, ≈13 cases/1000 people (1.262) for older
persons (≥ 60 y) relative to younger persons (< 60 y), ≈4
cases/1000 people (0.368) for non-supplement users
relative to supplement users, ≈4 cases/1000 people
(0.415) for serum creatinine ≥ 130 μmol/L relative to
serum creatinine < 130 μmol/L, and ≈5 cases/1000 peo-
ple (0.506) for serum vitamin B-12 < 148 pmol/L rela-
tive to serum vitamin B-12 ≥ 148 pmol/L. PAR%s for
serum MMA > 350 nmol/L were ≈25% for non-Hispanic
white in relation to non-non-Hispanic white, ≈41% for
older persons (≥ 60 y) in relation to younger persons (<
60 y), ≈12% for nonsupplement users in relation to sup-
plement users, ≈13% for serum creatinine ≥ 130 μmol/L
in relation to serum creatinine < 130 μmol/L, and ≈16%
for serum vitamin B-12 < 148 pmol/L in relation to
serum vitamin B-12 ≥ 148 pmol/L.
Additionally, to evaluate the impact of kidney dysfunc-
tion on the relation of serum MMA with age, race-eth-
nicity, supplement use, and serum vitamin B-12, we
calculated PAR and PAR% after excluding persons with
high serum creatinine (≥ 130 μmol/L). In this subset
population, PAR for serum high MMA were ≈8 cases/
1000 people (0.78) for non-Hispanic white relative to
combined non-Hispanic black and Mexican/Hispanic,
≈10 cases/1000 people (0.95) for ≥ 60 y old persons
relative to < 60 y old persons, ≈4 cases/1000 people
(0.44) for nonsuplement users relative to supplement
users, and ≈5 cases/1000 people (0.485) for serum
Table 1 Subject characteristics of study population:
National Health and Nutrition Examination Surveys
(NHANES), 1999-20041
Characteristic Value
All subjects, n 18569
Men, n(%) 9020 (49)
Women, n (%) 9549 (51)
Race-ethnicity
Non-Hispanic white, n (%) 8170 (44)
Non-Hispanic black, n (%) 4351 (23.4)
Mexican American/Hispanic, n (%) 6048 (32.6)
Age
12- < 18 y, n (%) 4546 (24)
≥ 60 y, n (%) 4427 (23.8)
Supplement users, n (%) 7681 (41)
Non-supplement users2, n (%) 10888 (59)
Serum creatinine ≥ 130 μmol/L, n (%) 331 (1.8)
Serum vitamin B-12 < 148 pmol/L, n (%) 349 (1.9)
Methylmalonic acid (nmol/L)3 129.3 (99.4, 169.4)
Prevalence of high methylmalonic acid
All subjects (%)4 3.1 ± 0.21
Serum creatinine < 130 μmol/L (%)4 2.7 ± 0.2
1NHANES 1999-2000, 2001-2002, and 2003-2004 were combined into one
analytic data set, 1999-2004. NHANESs 1999-2004 were conducted in the post-
folic acid fortification period.
2Persons who did not take vitamin/mineral supplements 1 month prior to the
survey
3Median and 25th and 75th percentiles. Distribution of serum MMA was not
normal
4Methylmalonic acid concentration > 350 nmol/L. Prevalence mean ± SE
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vitamin B-12 < 148 pmol/L group relative to vitamin B-
12 ≥ 148 pmol/L group (Table 5).
Discussion
In this report, we present the first data on prevalences,
PAR, and PAR% for high serum MMA in the post-folic
acid fortification period utilizing the data from surveys
of US population. The strength of this study is that we
combined 3 NHANES cycles into one database, which
not only resulted in a large sample size (n = 18569) but
also increased the precision of MMA estimate. We
found that likelihood of having high serum MMA was
significantly higher in white, older persons, nonsupple-
ment users, and persons with high serum creatinine and
low vitamin B-12 compared to their counterparts. Old
age, vitamin B-12 deficiency, renal dysfunction, and
non-supplement use contributed to PAR and PAR% for
high serum MMA.
In vitamin B-12 deficiency not only MMA but also
other undesirable products such as propionyl CoA,
methyl citrate (formed from condensation of propionyl
CoA and acetyl CoA by citrate synthase), and tHcy are
accumulated. Rare genetic defects in methlymalonyl
CoA mutase (mut 0 and mut-) and synthesis of defective
adenosylcobalamin are sources of MMA in some indivi-
duals [49]. Other sources of MMA include odd chain
fatty acids, certain amino acids, and intestinal bacteria
[10,50]. However, there were no data to what extent
these sources contribute to serum MMA. The deleter-
ious effects of vitamin B-12 deficiency on nervous sys-
tem are attributed to reduced methylation reactions due
to diminished supply of S-adenosylmethionine and also
possibly due to elevated MMA, propionyl CoA, methyl-
citrate [1-4], and tHcy [2,51].
In this study, the overall prevalence of serum MMA >
350 pmol/L is 3.1%. In older adults (≥ 60 y), it is 8.3%.
Prevalence of serum vitamin B-12 < 148 pmol/L is 2.0%.
In the prefortification period, prevalence of high MMA
(> 370 nmol/L) in persons aged ≥ 65 y was 16-18% (n =
1145) [31]. In the Los Angeles elderly people (> 60 y, n
= 725), 16.6% had high MMA (> 370-376 pmol/L) and
11.8% had serum vitamin B-12 < 140 pmol/L [32]. In
the Framingham study, 8% adults (26-83 y) had plasma
vitamin B-12 < 148 pmol/L [52]. In the Framingham
Table 2 Prevalence and likelihood of having high methylmalonic acid (MMA) in the post-folic acid fortification period:
National Health and Nutrition Examination Surveys (NHANES), 1999-20041
Characteristic Prevalence2% OR (95% CI)3 P-Value4 P-Value5
Sex 0.98
Men (n = 9020) 3.2 1.0 (0.83, 1.19) NS
Women (n = 9549)6 3.0 1.0 –
Race-ethnicity < 0.0001
Non-Hispanic white (n = 8170) 3.4 2.48 (1.78, 3.45) < 0.001
Non-Hispanic black (n = 4351)6 0.2 1.0 –
Mexican American/Hispanic (n = 6048) 3.0 2.77 (1.86, 4.14) 0.0003
Age < 0.0001
< 60 y (n = 14142)6 1.9 1.0 –
60 y (n = 4427) 8.3 4.01 (3.26, 4.92) < 0.0001
Supplement use7 < 0.0001
Yes (n = 7681)6 2.8 1.0 –
No (n = 10888) 3.5 1.82 (1.40, 2.37) < 0.0001
Serum creatinine8 < 0.0001
< 130 μmol/L (n = 18238)6 2.7 1.0 –
130 μmol/L (n = 331) 34.1 12.6 (8.99, 17.7) < 0.0001
Serum vitamin B-129 < 0.0001
< 148 pmol/L (n = 349) 27.6 13.5 (9.29, 19.6) < 0.0001
148 pmol/L (n = 18220)6 2.6 1.0 –
1n = 18569. NHANES 1999-2000, 2001-2002, and 2003-2004 were combined into one analytic data set, 1999-2004. NHANESs 1999-2004 were conducted in the
post-folic acid fortification period. Overall prevalence of serum MMA > 350 nmol/L was 3.1 ± 0.2 (% and SE)
2Population prevalence of serum MMA > 350 pmol/L was based on weighted sample size
3Odds ratio and 95% Wald confidence intervals in the multivariate logistic regression analysis
4Significance in comparison to the referent category within the variable (P for Wald c2)
5Overall significance of variable in the logistic regression model (P for Wald c2)
6Referent group
7Persons who took vitamin/mineral supplements 1 month prior to the survey
8Impaired renal function is defined as having serum creatinine ≥ 130 μmol/L
9Vitamin B-12 deficiency is defined as having serum vitamin B-12 < 148 pmol/L
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elderly population (67-96 y), 40.5% (222/548) had serum
vitamin B-12 < 258 pmol/L [9]. These studies were
based on white population. Thus, the existing data on
high MMA and low vitamin B-12 in the US vary by
population studied and criteria used to define vitamin
B-12 deficiency.
In this study, persons in the ≥ 60 y old age group are
> 4 times likely to have high serum MMA compared to
those in the younger age group (P < 0.001). A contribut-
ing factor for high serum MMA in older persons is kid-
ney dysfunction. In a separate analysis on ≥ 60 y old
population, the prevalence of high MMA in those with
serum creatinine ≥ 130 μmol/L is ≈33% (93/279) com-
pared to ≈7% (289/4148) in those with serum creatinine
< 130 μmol/L. Thus, a large portion of high MMA cases
can be attributed to renal dysfunction in older adults.
Further, vitamin B-12 deficiency is more common in
older persons primarily due to declined absorption of
vitamin B-12 from gut due to decreased secretion of
acid and pepsin from gastric atrophy which is a result of
bacterial colonization in the stomach [53,54]. Acid and
pepsin are needed to release the protein- bound vitamin
B-12 prior to its absorption. In some older adults, use of
medications such as H2 receptor antagonists and proton
pump inhibitors also lead to low vitamin B-12 status
due to malabsorption of protein-bound vitamin B-12
from achlorhydria [55]. In some, poor vitamin B-12 sta-
tus is attributed to autoimmune disorder associated with
H. pylori infection [56]. All these lead to elevated MMA.
Age is the strongest determinant of PAR (1.26) and
PAR% (40.5) for high serum MMA. After excluding per-
sons with kidney dysfunction, age still greatly contribu-
ted to PAR (0.95) and PAR% (35.2) for high MMA.
Thus, kidney dysfunction contributed ≈3 (1.26-0.95)/
1000 to the prevalence of serum high MMA. PAR and
PAR% for high serum MMA for serum vitamin B-12 <
148 pmol/L were ≈0.51 and 16.2, respectively. After
excluding persons with kidney dysfunction, the PAR and
PAR% for high MMA for low serum vitamin B-12 were
≈0.49 and 18.0, respectively (Table 4). This suggests that
low serum vitamin B-12 (< 148 pmol/L) is not as strong
determinant of PAR for high serum MMA.
In this study, PAR% for high MMA associated with
non-Hispanic white race is ≈25%, which suggests that
the race-ethnicity is a major determinant of serum
MMA in the US. In a separate analysis on this sample
(data not shown), we observed that non-Hispanic white
had significantly higher prevalence of serum vitamin B-
12 < 148 pmol/L (2.6%) compared to non-Hispanic
black (0.9%) or Mexican American/Hispanic (1.6%).
Thus, it is not surprising that non-Hispanic white had
higher prevalence of serum MMA compared to non-
Table 3 Prevalence and likelihood of having high serum methylmalonic acid (MMA) in persons with serum creatinine




OR (95% CI)3 P-Value4 P-Value5
Race-ethnicity < 0.0001
Non-Hispanic white (n = 7995)6 3.0 1.0 –
Non-Hispanic black (n = 4247) 0.8 0.28 (0.18, 0.44) < 0.0001
Mexican American/Hispanic (n = 5996) 2.8 1.1 (0.81, 1.50)n n/s
Age < 0.0001
< 60 y (n = 14090)6 1.8 1.0 –
60 y (n = 4148) 6.8 4.38 (3.58, 5.36) < 0.0001
Supplement use7 < 0.0001
Yes (n = 7506)6 2.3 1.0 –
No (n = 10732) 3.1 1.93 (1.48, 2.52) < 0.0001
Serum vitamin B-128 < 0.0001
< 148 pmol/L (n = 343) 26.3 13.3 (9.0, 19.5) < 0.0001
148 pmol/L (n = 17895)6 2.2 1.0 –
1 n = 18238; NHANES 1999-2000, 2001-2002, and 2003-2004 were combined into one analytic data set, 1999-2004. NHANESs 1999-2004 were conducted in the
post-folic acid fortification period. Data associated with sex variable are not shown because in logistic regression sex was not significantly related to serum MMA
concentrations (P < 0.98).
2Serum MMA > 350 pmol/L
3Odds ratio and 95% Wald confidence intervals in the multivariate logistic regression analysis
4Significance in comparison to the referent category within the variable (P for Wald c2)
5Overall significance of variable (sex, race-ethnicity, supplement use, age, serum creatinine, or serum vitamin B-12) in the logistic regression model (P for Wald c2)
6Referent group
7Persons who took vitamin/mineral supplements 1 month prior to the survey
8Vitamin B-12 deficiency is defined as having serum vitamin B-12 < 148 pmol/L
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Hispanic black or Mexican American/Hispanic. These
results support the observations made by others pre-
viously [32,33]. In the elderly, Morris et al [31] reported
high MMA in non-Hispanic white but the prevalence in
those subjects was similar to non-Hispanic black. Causes
for differences between races regarding MMA metabo-
lism needs further attention.
To date, there is no consensus regarding the cutoff
values for serum vitamin B-12 to define vitamin B-12
deficiency due to lack of diagnostic specificity and sensi-
tivity [57]. In few cases, serum vitamin B-12 does not
reflect true vitamin B-12 status because only 20-30% is
bound to holotranscobalamin (holoTC), a biologically
active vitamin B-12 fraction, capable of delivering vita-
min B-12 to tissues and the remaining majority is
bound to haptocorrin [58]. Because serum vitamin B-12
assay does not distinguish between haptocrrin and
holoTC
fractions, measurement of holoTC has been suggested
as a sensitive and early marker of vitamin B-12
Table 4 Population attributable risk (PAR) and
population attributable risk percentage (PAR%) for high
serum methylmalonic acid (MMA) in the National Health
and Nutrition Examination Surveys (NHANES), 1999-
20041
Characteristic Cases2 PAR3 PAR%4
Race-ethnicity5
Non-Hispanic white (n = 8170) 356 0.774 24.8
Non non-Hispanic white (n = 10399)6, 7 230 – –
Age5
< 60 y (n = 14142)6 204 – –
60 y (n = 4427) 382 1.262 40.5
Supplement use8, 9
Yes (n = 7681)6 252 – –
No (n = 10888) 334 0.368 11.8
Serum creatinine8, 10
< 130 μmol/L (n = 18238)6 477 – –
130 μmol/L (n = 331) 109 0.415 13.3
Serum vitamin B-128, 11
< 148 pmol/L (n = 349) 111 0.506 16.2
148 pmol/L (n = 18220)6 475 – –
1 n = 18569; NHANES 1999-2000, 2001-2002, and 2003-2004 were combined
into one analytic data set, 1999-2004. NHANESs, 1999-2004 were conducted
after the folic acid fortification commenced. PAR and PAR% for sex were not
presented because sex variable was not significantly related to high serum
MMA in the logistic regression model (P = 0.98).
2Number of cases with serum MMA > 350 nmol/L
3Prevalence of a condition/disease in the population due to the presence of
risk factor or prevalence of a condition/disease in the population that would
be reduced if risk factor was removed. PAR = (Prevalence of high MMATotal
sample × 100) - (Prevalence of high serum MMAReferent group × 100). Prevalence
of high serum MMATotal sample = Cases of high serum MMATotal sample/Sample
sizeTotal. Prevalence of high serum MMAReferent group = Cases of high serum
MMAReferent group/Sample sizeReferent group. PAR and PAR% were calculated
based on weighted sample. Weighted sample was used to account for
differential probabilities of selection and adjustments for non-coverage and
non-response bias.
4Percent of prevalence of a condition/disease in the population due to
presence of risk factor or percent of prevalence of a condition/disease in the
population that would be reduced if risk factor was removed. PAR% was
calculated based on weighted sample size. PAR% = (Prevalence of high serum
MMATotal sample - Prevalence of high serum MMAReferent group ÷ Prevalence of
high serum MMATotal sample) x100
5Non-modifiable risk factor for high serum MMA
6Referent group
7In order to achieve a dichotomous variable for race-ethnicity, non-Hispanic
black and Mexican American/Hispanic were combined into one category, non-
non-Hispanic white (non-white). Cases of serum MMA > 350 nmol/L for non-
Hispanic black and Mexican American/Hispanic were 65 and 165, respectively.
8Modifiable risk factor for high serum MMA
9Persons who took vitamin/mineral supplements 1 month prior to the survey
10Kidney dysfunction was defined as having serum creatinine ≥ 130 μmol/L
11Vitamin B-12 deficiency was defined as having serum vitamin B-12 < 148
pmol/L
Table 5 Population attributable risk (PAR) and
population attributable risk percentages (PAR%) for high
serum methylmalonic acid (MMA) for persons with serum
creatinine < 130 μmol/L in the National Health and
Nutrition Examination Surveys (NHANES), 1999-20041
Characteristic Cases2 PAR3 PAR%4
Race-ethnicity5
Non-Hispanic white (n = 7995) 297 0.783 29.0
Non non-Hispanic white (n = 10243)6, 7 180 – –
Age5
< 60 y (n = 14090)6 188 – –
60 y (n = 4148) 289 0.950 35.2
Supplement use8, 9
Yes (n = 7506)6 192 – –
No (n = 10732) 285 0.444 16.4
Serum vitamin B-128, 10
< 148 pmol/L (n = 343) 105 0.485 18.0
148 pmol/L (n = 17895)6 372 – –
1n = 18238; NHANES 1999-2000, 2001-2002, and 2003-2004 were combined
into one analytic data set, 1999-2004. NHANESs, 1999-2004 were conducted
after the folic acid fortification commenced. PAR and PAR% for sex were not
presented because sex variable was not significantly related to high serum
MMA in the logistic regression model (P = 0.98)
2Number of cases with serum MMA > 350 nmol/L
3Incidence of a condition/disease in the population due to the presence of
risk factor or incidence of a condition/disease in the population that would be
reduced if risk factor was removed. PAR was calculated based on weighted
sample size. PAR = (Incidence of high MMATotal sample × 100) - (Incidence of
high serum MMAReferent group × 100). Incidence of high serum MMATotal sample
= Cases of high serum MMATotal sample/Sample sizeTotal. Incidence of high
serum MMAReferent group = Cases of high serum MMAReferent group/Sample
sizeReferent group.
4Percent of incidence of a condition/disease in the population due to
presence of risk factor or percent of incidence of a condition/disease in the
population that would be reduced if risk factor was removed. PAR% was
calculated based on weighted sample size. PAR% = (Incidence of high serum
MMATotal sample - Incidence of high serum MMAReferent group ÷ Incidence of
high serum MMATotal sample) x100
5Non-modifiable risk factor for high serum MMA
6Referent group
7In order to achieve a dichotomous variable for race-ethnicity, non-Hispanic
black and Mexican American/Hispanic were combined into one category, non-
non-Hispanic white.
8Modifiable risk factor for high serum MMA
9Persons who took vitamin/mineral supplements 1 month prior to the survey
10Vitamin B-12 deficiency was defined as having serum vitamin B-12 < 148
pmol/L
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deficiency [59]. However, like MMA, holoTC is also ele-
vated in renal dysfunction [60] leaving no universal gold
standard for the measurement of vitamin B-12
deficiency.
There are some assumptions in calculating PAR and
PAR%. These are (a) cause and effect relationship exists
between serum MMA and renal dysfunction and serum
vitamin B-12 and (b) serum creatinine > 130 μmol/L,
serum vitamin B-12 < 148 pmol/L, and serum MMA >
350 nmol/L were used to define kidney dysfunction,
vitamin B-12 deficiency, and high serum MMA,
respectively.
Conclusions
In conclusion, a reduction of ≈5 cases of high MMA/
1000 people is expected if serum vitamin B-12 in the
US is improved to or > 148 pmol/L. Such a decrease
represents ≈16% reduction of prevalence of high MMA.
After excluding persons with kidney dysfunction, PAR%
for high MMA for vitamin B-12 deficiency is marginally
increased (from 16.2 to 18) which further strengthens
our notion that even in the absence of renal dysfunction
a large portion of high MMA cases might not be
affected with the improvement in vitamin B-12 status.
Regardless of kidney function, prevalence of high serum
MMA would be reduced by 16-18% (PAR is ≈5 cases/
1000 people) in the US population if the risk factor,
vitamin B-12 deficiency is eliminated.
Because a large portion of high serum MMA cases in
the US are not related to vitamin B-12 status (serum
vitamin B-12 < 148 pmol/L), caution should be used in
attributing high serum MMA to vitamin B-12 defi-
ciency even in the absence of kidney dysfunction.
Given the depressed absorption of vitamin B-12 and
increased prevalence of renal dysfunction, it is unlikely
that increased oral intake of vitamin B-12 would dra-
matically reduce the prevalence of high serum MMA
in older adults. It is important to monitor the indica-
tors of vitamin B-12 status such as serum MMA con-
centrations, on a continuous basis because of possible
negative impact of high folic acid intakes on vitamin
B-12 homeostasis in the post-folic acid fortification
period.
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